Ventyx Historical Balance Sheet

VTYX Stock

USD 1.22 0.06 4.69%

Trend analysis of Ventyx Biosciences balance sheet accounts such as Total Assets of 223.3 M, Short Long Term Debt Total of 9.1 M, Other Current Liabilities of 7.6 M or Total Current Liabilities of 12 M provides information on Ventyx Biosciences' total assets, liabilities, and equity, which is the actual value of Ventyx Biosciences to its prevalent stockholders. By breaking down trends over time using Ventyx Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Ventyx Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ventyx Biosciences is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Ventyx Stock please use our How to Invest in Ventyx Biosciences guide.

About Ventyx Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Ventyx Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Ventyx Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ventyx Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ventyx currently owns. An asset can also be divided into two categories, current and non-current.

Ventyx Biosciences Balance Sheet Chart

At this time, Ventyx Biosciences' Total Stockholder Equity is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 427.3 M in 2025, whereas Total Assets are likely to drop slightly above 223.3 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Ventyx Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ventyx Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Ventyx Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ventyx Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Ventyx Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Ventyx Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Ventyx Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ventyx Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Ventyx Stock please use our How to Invest in Ventyx Biosciences guide.At this time, Ventyx Biosciences' Total Stockholder Equity is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 427.3 M in 2025, whereas Total Assets are likely to drop slightly above 223.3 M in 2025.

	2023	2024	2025 (projected)
Short and Long Term Debt Total	12.5M	10.8M	9.1M
Total Assets	277.7M	276.6M	223.3M

Short Long Term Debt Total Total Assets

Ventyx Biosciences balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Other Liab	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Capital Surpluse
Total Assets		0.22	0.92	0.95	0.17	0.76	-0.91	-0.79	0.97	0.96	0.84	1.0	0.63	0.01	0.94	0.94	0.64	1.0	1.0	1.0	-0.39	0.45	0.6	0.78	-0.84	0.81
Short Long Term Debt Total	0.22		0.45	0.4	0.74	0.52	0.09	-0.62	0.26	0.09	0.56	0.17	0.65	0.81	0.41	0.44	0.84	0.18	0.23	0.21	-0.43	0.49	0.71	0.54	-0.48	0.52
Other Current Liab	0.92	0.45		0.99	0.41	0.79	-0.79	-0.84	0.94	0.88	0.8	0.91	0.68	0.12	0.93	0.94	0.75	0.9	0.93	0.92	-0.36	0.41	0.73	0.78	-0.88	0.83
Total Current Liabilities	0.95	0.4	0.99		0.34	0.8	-0.83	-0.83	0.97	0.91	0.82	0.94	0.65	0.11	0.95	0.94	0.75	0.94	0.96	0.95	-0.36	0.4	0.7	0.78	-0.89	0.83
Total Stockholder Equity	0.17	0.74	0.41	0.34		0.58	0.15	-0.71	0.13	0.03	0.22	0.11	0.78	0.25	0.37	0.43	0.46	0.15	0.17	0.16	-0.68	0.73	0.88	0.59	-0.46	0.52
Net Tangible Assets	0.76	0.52	0.79	0.8	0.58		-0.45	-0.93	0.73	0.58	0.62	0.72	0.85	0.08	0.9	0.86	0.66	0.74	0.75	0.74	-0.68	0.73	0.87	0.94	-0.97	0.95
Net Debt	-0.91	0.09	-0.79	-0.83	0.15	-0.45		0.49	-0.91	-0.98	-0.7	-0.94	-0.28	0.15	-0.74	-0.75	-0.42	-0.92	-0.92	-0.92	0.1	-0.11	-0.28	-0.45	0.59	-0.52
Retained Earnings	-0.79	-0.62	-0.84	-0.83	-0.71	-0.93	0.49		-0.73	-0.64	-0.73	-0.75	-0.94	-0.2	-0.88	-0.91	-0.73	-0.77	-0.78	-0.78	0.77	-0.83	-0.96	-0.94	0.9	-0.92
Accounts Payable	0.97	0.26	0.94	0.97	0.13	0.73	-0.91	-0.73		0.97	0.83	0.98	0.52	0.09	0.91	0.89	0.7	0.96	0.98	0.98	-0.31	0.32	0.56	0.69	-0.85	0.75
Cash	0.96	0.09	0.88	0.91	0.03	0.58	-0.98	-0.64	0.97		0.78	0.98	0.42	-0.02	0.82	0.83	0.57	0.96	0.97	0.97	-0.27	0.27	0.45	0.57	-0.71	0.62
Long Term Debt	0.84	0.56	0.8	0.82	0.22	0.62	-0.7	-0.73	0.83	0.78		0.83	0.63	0.52	0.81	0.85	0.87	0.82	0.84	0.84	-0.32	0.43	0.57	0.71	-0.7	0.74
Cash And Short Term Investments	1.0	0.17	0.91	0.94	0.11	0.72	-0.94	-0.75	0.98	0.98	0.83		0.56	-0.01	0.91	0.91	0.62	1.0	1.0	1.0	-0.36	0.39	0.55	0.72	-0.82	0.77
Common Stock Shares Outstanding	0.63	0.65	0.68	0.65	0.78	0.85	-0.28	-0.94	0.52	0.42	0.63	0.56		0.2	0.78	0.83	0.62	0.61	0.61	0.6	-0.73	0.88	0.94	0.94	-0.77	0.9
Non Current Liabilities Total	0.01	0.81	0.12	0.11	0.25	0.08	0.15	-0.2	0.09	-0.02	0.52	-0.01	0.2		0.07	0.1	0.73	-0.03	0.02	0.01	-0.12	0.15	0.23	0.13	-0.09	0.12
Other Current Assets	0.94	0.41	0.93	0.95	0.37	0.9	-0.74	-0.88	0.91	0.82	0.81	0.91	0.78	0.07		0.98	0.71	0.93	0.94	0.93	-0.44	0.54	0.74	0.92	-0.95	0.95
Other Stockholder Equity	0.94	0.44	0.94	0.94	0.43	0.86	-0.75	-0.91	0.89	0.83	0.85	0.91	0.83	0.1	0.98		0.71	0.93	0.94	0.94	-0.49	0.61	0.79	0.92	-0.9	0.94
Total Liab	0.64	0.84	0.75	0.75	0.46	0.66	-0.42	-0.73	0.7	0.57	0.87	0.62	0.62	0.73	0.71	0.71		0.6	0.65	0.64	-0.38	0.42	0.68	0.66	-0.72	0.68
Net Invested Capital	1.0	0.18	0.9	0.94	0.15	0.74	-0.92	-0.77	0.96	0.96	0.82	1.0	0.61	-0.03	0.93	0.93	0.6		1.0	1.0	-0.39	0.44	0.58	0.76	-0.83	0.8
Total Current Assets	1.0	0.23	0.93	0.96	0.17	0.75	-0.92	-0.78	0.98	0.97	0.84	1.0	0.61	0.02	0.94	0.94	0.65	1.0		1.0	-0.38	0.42	0.6	0.76	-0.84	0.8
Net Working Capital	1.0	0.21	0.92	0.95	0.16	0.74	-0.92	-0.78	0.98	0.97	0.84	1.0	0.6	0.01	0.93	0.94	0.64	1.0	1.0		-0.38	0.42	0.59	0.76	-0.84	0.8
Other Liab	-0.39	-0.43	-0.36	-0.36	-0.68	-0.68	0.1	0.77	-0.31	-0.27	-0.32	-0.36	-0.73	-0.12	-0.44	-0.49	-0.38	-0.39	-0.38	-0.38		-0.95	-0.8	-0.64	0.56	-0.55
Non Currrent Assets Other	0.45	0.49	0.41	0.4	0.73	0.73	-0.11	-0.83	0.32	0.27	0.43	0.39	0.88	0.15	0.54	0.61	0.42	0.44	0.42	0.42	-0.95		0.85	0.77	-0.59	0.68
Net Receivables	0.6	0.71	0.73	0.7	0.88	0.87	-0.28	-0.96	0.56	0.45	0.57	0.55	0.94	0.23	0.74	0.79	0.68	0.58	0.6	0.59	-0.8	0.85		0.87	-0.8	0.83
Common Stock Total Equity	0.78	0.54	0.78	0.78	0.59	0.94	-0.45	-0.94	0.69	0.57	0.71	0.72	0.94	0.13	0.92	0.92	0.66	0.76	0.76	0.76	-0.64	0.77	0.87		-0.9	0.99
Retained Earnings Total Equity	-0.84	-0.48	-0.88	-0.89	-0.46	-0.97	0.59	0.9	-0.85	-0.71	-0.7	-0.82	-0.77	-0.09	-0.95	-0.9	-0.72	-0.83	-0.84	-0.84	0.56	-0.59	-0.8	-0.9		-0.94
Capital Surpluse	0.81	0.52	0.83	0.83	0.52	0.95	-0.52	-0.92	0.75	0.62	0.74	0.77	0.9	0.12	0.95	0.94	0.68	0.8	0.8	0.8	-0.55	0.68	0.83	0.99	-0.94

Click cells to compare fundamentals

Ventyx Biosciences Account Relationship Matchups

Ventyx Biosciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	245K	291.5M	371.4M	277.7M	276.6M	223.3M
Other Current Liab	301K	7.6M	9.1M	15.5M	8.6M	7.6M
Total Current Liabilities	1.4M	12.3M	16.4M	22.3M	12.8M	12.0M
Total Stockholder Equity	(30.7M)	(117.8M)	(226.2M)	243.9M	254.0M	266.7M
Net Debt	12.4M	(70.8M)	(63.3M)	(39.1M)	(16.5M)	(17.3M)
Retained Earnings	(32.5M)	(117.8M)	(226.2M)	(419.2M)	(554.3M)	(526.6M)
Accounts Payable	1.1M	4.7M	6.4M	5.8M	3.1M	3.9M
Cash	244K	70.8M	64.8M	51.6M	27.3M	39.4M
Cash And Short Term Investments	244K	286.7M	356.6M	252.2M	217.3M	204.1M
Liabilities And Stockholders Equity	245K	(105.5M)	(208.7M)	277.7M	276.6M	290.4M
Non Current Liabilities Total	29.5M	4.7M	1.1M	11.5M	9.7M	8.1M
Other Current Assets	1K	4.4M	12.7M	12.1M	12.3M	7.6M
Other Stockholder Equity	1.8M	397.1M	581.2M	663.2M	808.2M	449.5M
Total Liab	30.9M	12.3M	17.5M	33.8M	22.5M	22.3M
Net Invested Capital	(18.0M)	279.2M	353.9M	243.9M	254.0M	204.0M
Total Current Assets	245K	263.0M	330.7M	264.3M	229.6M	199.5M
Net Working Capital	(1.2M)	250.7M	314.3M	242.1M	216.8M	187.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Ventyx Stock Analysis

When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ventyx Historical Balance Sheet

About Ventyx Balance Sheet Analysis

Ventyx Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Ventyx Biosciences balance sheet Correlations

Ventyx Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ventyx Biosciences balance sheet Accounts

Also Currently Popular

Additional Tools for Ventyx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 0.98	Net Debt
Retained Earnings Total Equity	- 0.97	Net Tangible Assets
Net Receivables	- 0.96	Retained Earnings
Non Currrent Assets Other	- 0.95	Other Liab
Retained Earnings Total Equity	- 0.95	Other Current Assets
Capital Surpluse	- 0.94	Retained Earnings Total Equity